Table 5.
KEGG enrichment analysis of immune-related mRNAs in the ceRNA regulatory network in GC.
| Term | Count | p-value | FDR | mRNAs |
|---|---|---|---|---|
| hsa05200:Pathways in cancer | 16 | 8.65E−09 | 9.34E−07 | MAP2K1, PRKCB, F2R, WNT5A, TGFBR1, PGF, NRAS, FGF14, TRAF3, CDK4, AGTR1, RAC1, FGF13, BID, MET, FGF10 |
| hsa04060:Cytokine–cytokine receptor interaction | 11 | 2.17E−06 | 1.17E−04 | GHR, CXCL9, TNFRSF12A, TNFSF15, TNFRSF9, LIF, TNFSF11, TNFRSF10B, LIFR, IL1RAP, TGFBR1 |
| hsa05218:Melanoma | 7 | 5.05E−06 | 1.47E−04 | MAP2K1, NRAS, FGF14, CDK4, FGF13, MET, FGF10 |
| hsa04015:Rap1 signaling pathway | 10 | 5.43E−06 | 1.47E−04 | MAP2K1, NRAS, FGF14, PRKCB, F2R, RAC1, FGF13, MET, PGF, FGF10 |
| hsa04014:Ras signaling pathway | 10 | 9.89E−06 | 2.14E−04 | MAP2K1, NRAS, FGF14, PRKCB, RAC1, FGF13, PAK3, MET, PGF, FGF10 |
| hsa04810:Regulation of actin cytoskeleton | 9 | 4.54E−05 | 7.33E−04 | MAP2K1, NRAS, FGF14, F2R, RAC1, FGF13, PAK3, VAV2, FGF10 |
| hsa04151:PI3K–Akt signaling pathway | 11 | 4.75E−05 | 7.33E−04 | GHR, MAP2K1, NRAS, FGF14, CDK4, F2R, RAC1, FGF13, MET, PGF, FGF10 |
| hsa04664:Fc epsilon RI signaling pathway | 6 | 6.55E−05 | 8.85E−04 | LYN, MAP2K1, NRAS, PRKCB, RAC1, VAV2 |
| hsa04650:Natural killer cell mediated cytotoxicity | 7 | 1.12E−04 | 0.001343 | MAP2K1, NRAS, PRKCB, TNFRSF10B, RAC1, BID, VAV2 |
| hsa05211:Renal cell carcinoma | 5 | 7.86E−04 | 0.008494 | MAP2K1, NRAS, RAC1, PAK3, MET |
| hsa04662:B-cell receptor signaling pathway | 5 | 9.30E−04 | 0.009003 | LYN, MAP2K1, NRAS, RAC1, VAV2 |
| hsa04010:MAPK signaling pathway | 8 | 0.001 | 0.009003 | MAP2K1, NRAS, FGF14, PRKCB, RAC1, FGF13, TGFBR1, FGF10 |
| hsa04612:Antigen processing and presentation | 5 | 0.001337 | 0.011104 | PSME3, TAP2, TAP1, CALR, CTSB |
| hsa05205:Proteoglycans in cancer | 7 | 0.001573 | 0.012138 | MAP2K1, NRAS, PRKCB, WNT5A, PLAUR, RAC1, MET |
| hsa04510:Focal adhesion | 7 | 0.00183 | 0.013074 | MAP2K1, PRKCB, RAC1, PAK3, MET, PGF, VAV2 |
| hsa04666:Fc gamma R-mediated phagocytosis | 5 | 0.001937 | 0.013074 | LYN, MAP2K1, PRKCB, RAC1, VAV2 |
| hsa04660:T-cell receptor signaling pathway | 5 | 0.003655 | 0.023221 | MAP2K1, NRAS, CDK4, PAK3, VAV2 |
| hsa05223:Non-small cell lung cancer | 4 | 0.005345 | 0.032068 | MAP2K1, NRAS, PRKCB, CDK4 |
| hsa04062:Chemokine signaling pathway | 6 | 0.006326 | 0.034272 | LYN, MAP2K1, CXCL9, NRAS, RAC1, VAV2 |
| hsa04730:Long-term depression | 4 | 0.006482 | 0.034272 | LYN, MAP2K1, NRAS, PRKCB |
| hsa04370:VEGF signaling pathway | 4 | 0.006787 | 0.034272 | MAP2K1, NRAS, PRKCB, RAC1 |
| hsa04071:Sphingolipid signaling pathway | 5 | 0.006981 | 0.034272 | MAP2K1, NRAS, PRKCB, RAC1, BID |
| hsa05214:Glioma | 4 | 0.008093 | 0.035418 | MAP2K1, NRAS, PRKCB, CDK4 |
| hsa05212:Pancreatic cancer | 4 | 0.008093 | 0.035418 | MAP2K1, CDK4, RAC1, TGFBR1 |
| hsa04024:cAMP signaling pathway | 6 | 0.008199 | 0.035418 | MAP2K1, FSHB, F2R, RAC1, ADRB2, VAV2 |
| hsa05220:Chronic myeloid leukemia | 4 | 0.010713 | 0.044498 | MAP2K1, NRAS, CDK4, TGFBR1 |
| hsa04550:Signaling pathways regulating pluripotency of stem cells | 5 | 0.01188 | 0.047521 | MAP2K1, NRAS, WNT5A, LIF, LIFR |
FDR, false discovery rate.